The 2018 update of the Canadian Stroke Best Practice Recommendations for Acute Stroke Management, 6th edition, is a comprehensive summary of current evidence-based recommendations, appropriate for use by healthcare providers and system planners caring for persons with very recent symptoms of acute stroke or transient ischemic attack. The recommendations are intended for use by a interdisciplinary team of clinicians across a wide range of settings and highlight key elements involved in prehospital and Emergency Department care, acute treatments for ischemic stroke, and acute inpatient care. The most notable changes included in this 6th edition are the renaming of the module and its integration of the formerly separate modules on prehospital and emergency care and acute inpatient stroke care. The new module, Acute Stroke Management: Prehospital, Emergency Department, and Acute Inpatient Stroke Care is now a single, comprehensive module addressing the most important aspects of acute stroke care delivery. Other notable changes include the removal of two sections related to the emergency management of intracerebral hemorrhage and subarachnoid hemorrhage. These topics are covered in a new, dedicated module, to be released later this year. The most significant recommendation updates are for neuroimaging; the extension of the time window for endovascular thrombectomy treatment out to 24 h; considerations for treating a highly selected group of people with stroke of unknown time of onset; and recommendations for dual antiplatelet therapy for a limited duration after acute minor ischemic stroke and transient ischemic attack. This module also emphasizes the need for increased public and healthcare provider's recognition of the signs of stroke and immediate actions to take; the important expanding role of paramedics and all emergency medical services personnel; arriving at a stroke-enabled Emergency Department without delay; and launching local healthcare institution code stroke protocols. Revisions have also been made to the recommendations for the triage and assessment of risk of recurrent stroke after transient ischemic attack/minor stroke and suggested urgency levels for investigations and initiation of management strategies. The goal of this updated guideline is to optimize stroke care across Canada, by reducing practice variations and reducing the gap between current knowledge and clinical practice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/1747493018786616 | DOI Listing |
JAMA Intern Med
January 2025
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Importance: Evidence on cardiovascular benefits and safety of sodium-glucose cotransporter 2 (SGLT-2) inhibitors is mainly from placebo-controlled trials. Therefore, the comparative effectiveness and safety of individual SGLT-2 inhibitors remain unknown.
Objective: To compare the use of canagliflozin or dapagliflozin with empagliflozin for a composite outcome (myocardial infarction [MI] or stroke), heart failure hospitalization, MI, stroke, all-cause death, and safety outcomes, including diabetic ketoacidosis (DKA), lower-limb amputation, bone fracture, severe urinary tract infection (UTI), and genital infection and whether effects differed by dosage or cardiovascular disease (CVD) history.
JAMA Neurol
January 2025
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Importance: Trials have not demonstrated superiority of alteplase or tenecteplase vs standard care in patients with mild stroke and have raised safety concerns. Prourokinase is an alternative fibrinolytic that may have a favorable safety profile, and the benefit-risk profile of prourokinase in mild stroke is unknown.
Objective: To investigate the efficacy and safety of prourokinase in mild ischemic stroke within 4.
Stem Cells Dev
January 2025
Department of Clinical Pharmacy and Pharmacy Practices, Faculty of Pharmacy, University Malaya, Kuala Lumpur, Malaysia.
Hypertension, commonly known as high blood pressure, is a significant health issue that increases the risk of cardiovascular diseases, stroke, and renal failure. This condition broadly encompasses both primary and secondary forms. Despite extensive research, the underlying mechanisms of systemic arterial hypertension-particularly primary hypertension, which has no identifiable cause and is affected by genetic and lifestyle agents-remain complex and not fully understood.
View Article and Find Full Text PDFUltrasound J
January 2025
Health Sciences North Research Institute, Sudbury, ON, Canada.
The duration of mechanical systole-also termed the flow time (FT) or left ventricular ejection time (LVET)-is measured by Doppler ultrasound and increasingly used as a stroke volume (SV) surrogate to guide patient care. Nevertheless, confusion exists as to the determinants of FT and a critical evaluation of this measure is needed. Using Doppler ultrasound of the left ventricular outflow tract velocity time integral (LVOT VTI) as well as strain and strain rate echocardiography as grounding principles, this brief commentary offers a model for the independent influences of FT.
View Article and Find Full Text PDFRadiology
January 2025
From the Dept of Diagnostic and Interventional Neuroradiology, Univ Medical Ctr Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany (L.M., G.B., P.S., J.F., C.P.S.); Dept of Diagnostic and Interventional Neuroradiology, Hosp Bremen-Mitte, Bremen, Germany (M.A., P.P.); Interventional Neuroradiology Section, Dept of Radiology, Donostia Univ Hosp, Donostia-San Sebastián, Spain (Á.L., J.Á.L.); Clinic for Radiology, Section for Interventional Radiology, Univ of Münster and Univ Hosp Münster, Münster, Germany (W.S., H.K., C.P.S.); Dept of Neuroradiology, Westpfalz-Klinikum, Kaiserslautern, Germany (W.N.); Dept of Neuroradiology, Otto-von-Guericke-Universitätsklinikum Magdeburg, Magdeburg, Germany (D.B., M.T.); Inst for Diagnostic and Interventional Radiology and Neuroradiology, Univ Hosp Essen, Essen, Germany (H.S., C.D.); Dept of Neuroradiology, Univ of Cologne, Cologne, Germany (C.K., C.Z.); Dept of Neuroradiology, Univ Hosp Aachen, Aachen, Germany (C.W., M. Möhlenbruch); Dept of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, School of Medicine, Technical Univ Munich, Munich, Germany (M.R.H.P., C.M.); Inst of Neuroradiology, Univ Hosps, LMU Munich, Munich, Germany (H.Z.); Dept of Diagnostic and Interventional Neuroradiology, Univ Medical Ctr Goettingen, Goettingen, Germany (M. Ernst, A.J.); Interventional Neuroradiology, Dept of Radiology, Hosp Clínico San Carlos, Madrid, Spain (M.M.G., C.P.G.); Dept of Neuroradiology, Hosp Universitario La Paz, Madrid, Spain (P.N., A.F.P.); Div of Neurology, Dept of Medicine (L.Y., B.T.), and Div of Interventional Radiology, Dept of Diagnostic Imaging (A.G.), National Univ Health System, Singapore; Yong Loo Lin School of Medicine, National Univ of Singapore, Singapore (L.Y., B.T., A.G.); Inst of Neuroradiology, Charité Universitätsmedizin Berlin, Berlin, Germany (E.S., M. Miszczuk); Dept of Neuroradiology, Clinic and Policlinic of Radiology, Univ Hosp Halle/Saale, Halle, Germany (S.S.); Dept of Radiology and Neuroradiology, Stadtspital Zürich, Zürich, Switzerland (P.S.); Dept of Diagnostic and Interventional Neuroradiology, Univ Hosp Basel, Basel, Switzerland (P.S., M.P.); Depts of Interventional Neuroradiology (J.Z.P.) and Neurology (G.P.), Hosp Clínico Universitario Virgen de la Arrixaca, Murcia, Spain; Dept of Neuroradiology, Karolinska Univ Hosp and Dept of Clinical Neuroscience, Karolinska Inst, Stockholm, Sweden (F.A., T.A.); Dept of Medical Imaging, AZ Groeninge, Kortrijk, Belgium (T.A.); Dept of Radiology, Comenius Univ's Jessenius Faculty of Medicine and Univ Hosp, Martin, Slovakia (K.Z.); Dept of Radiology, Aretaieion Univ Hosp, National and Kapodistrian Univ of Athens, Athens, Greece (P.P.); Dept of Neuroradiology, Univ Hosp Marburg, Marburg, Germany (A.K.); Dept of Neuroradiology, Univ Hosp of Bonn, Bonn, Germany (F.D.); and Dept of Neuroradiology, Alfried Krupp Krankenhaus, Essen, Germany (M. Elsharkawy).
Background Symptomatic acute occlusions of the internal carotid artery (ICA) below the circle of Willis can cause a variety of stroke symptoms, even if the major intracranial cerebral arteries remain patent; however, outcome and safety data are limited. Purpose To compare treatment effects and procedural safety of endovascular treatment (EVT) and best medical treatment (BMT) in patients with symptomatic acute occlusions of the ICA below the circle of Willis. Materials and Methods This retrospective, multicenter cohort study from 22 comprehensive stroke centers in Europe and Asia includes patients treated between January 1, 2008, and December 31, 2022.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!